This is a phase 2, randomized, double-blinded study investigating the efficacy and safety of three dose levels of subcutaneous semaglutide once daily versus placebo in subjects with non-alcoholic steatohepatitis.
The primary objective is NASH (non-alcoholic steatohepatitis) resolution without worsening of fibrosis.
Please complete the form below if you are interested in joining a clinical study. Please note that not all who apply are accepted into a trial.
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.